Abstract
Proteomics for biomedicine: a half‐completed journey
Highlights
I studied physics and mathematics until the master’s level, I always knew that I wanted to get into biology, whose golden age I was sure was happening in my lifetime
» I took one of the most ambitious and stressful decisions of my professional life: I bet everything on the success of mass spectrometry-based protein
When in 1992 I was offered a group leader position at the European Molecular Biology Laboratory (EMBL), I took one of the most ambitious and stressful decisions of my professional life: I bet everything on the success of mass spectrometry (MS)based protein characterization
Summary
I studied physics and mathematics until the master’s level, I always knew that I wanted to get into biology, whose golden age I was sure was happening in my lifetime. At first there was little interest in ‘electrospray’, but as soon as it became clear that large, intact proteins survive this process (Mann et al, 1989; Meng et al, 1988), the community was hooked This included the Nobel Prize committee, who gave John a share of their prize for chemistry in 2002. When in 1992 I was offered a group leader position at the European Molecular Biology Laboratory (EMBL), I took one of the most ambitious and stressful decisions of my professional life: I bet everything on the success of mass spectrometry (MS)based protein characterization. I continued to be involved in programming too, which gave us quite a competitive edge in devising new strategies to retrieve biologically meaningful data from proteomics During these years we started to apply proteomics to define the members of protein complexes. ESI-MS Electrospray ionization mass spectrometry (using LC-ESI-LTQ-Orbitrap Velos) C-trap
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
